DUBLIN,
April 5, 2019 /CNW/
-- Endo International plc (NASDAQ: ENDP) announced
today that one of its operating companies, Par Pharmaceutical
(Par), has begun shipping an authorized generic version of Merck's
PROVENTIL® (albuterol sulfate)
HFA Inhalation Aerosol, 120mcg. Endo's subsidiary,
Endo Procurement Operations Limited, recently entered into an
exclusive U.S. supply and distribution agreement with a subsidiary
of Merck & Co., Inc., of Kenilworth,
N.J. allowing Par to launch and distribute an authorized
generic of the product.
"We are very pleased to add albuterol sulfate to Par's
portfolio and to be able to offer the authorized generic of the
product to patients," said Tony
Pera, President of Par Pharmaceutical. "Par has partnered
with Merck several times to bring an authorized generic product to
market and we are proud to be a reliable, quality
supplier."
PROVENTIL ® is a registered trademark of Merck
Sharp & Dohme Corp.
About Endo International plc
Endo
International plc (NASDAQ: ENDP) is a highly focused generics and
specialty branded pharmaceutical company delivering quality
medicines to patients in need through excellence in development,
manufacturing and commercialization. Endo has global headquarters
in Dublin, Ireland, and U.S.
headquarters in Malvern, PA. Learn
more at www.endo.com.
About Par Pharmaceutical
Par
Pharmaceutical, headquartered in Chestnut
Ridge, NY, develops, manufactures and markets safe,
innovative and cost-effective generic pharmaceutical and branded
injectable products that help improve patient quality of life. Par,
among the top leaders in the U.S. generics industry, possesses a
portfolio that includes sterile injectables, alternative dosage
forms and many other differentiated products. Par is
advancing a robust research and development (R&D) pipeline
of potential products. Par is an operating company of Endo
International plc. Learn more at www.endo.com or
www.parpharm.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press
release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities legislation. Statements including
words such as "believes," "expects," "anticipates," "intends,"
"estimates," "plan," "will," "may," "look forward," "intend,"
"guidance," "future" or similar expressions are forward-looking
statements. Because these statements reflect Endo's current views,
expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties.
Investors should note that many factors, as more fully described
under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and
Form 8-K filings with the Securities and Exchange
Commission and in Canada on
the System for Electronic Data Analysis and Retrieval and as
otherwise enumerated herein or therein, could individually or in
the aggregate affect Endo's future financial results and could
cause Endo's actual results to differ materially from those
expressed in the forward-looking statements or from historical
results. The forward-looking statements in this press release are
qualified by these risk factors. Endo assumes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise, except as may
be required under applicable securities laws.
View original
content:http://www.prnewswire.com/news-releases/endo-begins-shipment-of-authorized-generic-version-of-proventil-albuterol-sulfate-hfa-inhalation-aerosol-in-the-united-states-300824983.html
SOURCE Endo International plc